Evidence map›Paper›PMID 30655948›Full record

ArticleACS medicinal chemistry letters2019

Synthesis, Biological Evaluation and Structure-Activity Relationships of Diflapolin Analogues as Dual sEH/FLAP Inhibitors.

Lisa Vieider, Erik Romp, Veronika Temml, Jana Fischer, Christian Kretzer, Martin Schoenthaler, Abdulla Taha, Victor Hernández-Olmos, Sonja Sturm, Daniela Schuster and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Quinazoline-4(3ACS omega · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lisa VieiderInstitute of Pharmacy, Department of Pharmaceutical Chemistry, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.
Erik RompChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Veronika TemmlInstitute of Pharmacy, Department of Pharmacognosy, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.
Jana FischerChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Christian KretzerChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Martin SchoenthalerInstitute of Pharmacy, Department of Pharmaceutical Chemistry, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.
Abdulla TahaChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Victor Hernández-OlmosFraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany.
Sonja SturmInstitute of Pharmacy, Department of Pharmacognosy, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.
Daniela SchusterInstitute of Pharmacy, Department of Pharmaceutical Chemistry, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.
Oliver WerzChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Ulrike GarschaChair of Pharmaceutical/Medicinal Chemistry, Friedrich-Schiller University Jena, Philosophenweg 14, D-07743 Jena, Germany.
Barbara MatuszczakInstitute of Pharmacy, Department of Pharmaceutical Chemistry, Center for Chemistry and Biomedicine, University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria.

Funding

Austrian Science Fund FWF T 942
6 · The paper itself

Abstract

A series of derivatives of the potent dual soluble epoxide hydrolase (sEH)/5-lipoxygenase-activating protein (FLAP) inhibitor diflapolin was designed, synthesized, and characterized by

Identifiers

PMID30655948
PMCPMC6331193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.